Opdivo (Nivolumab) vs Zynyz (retifanlimab-dlwr)
Opdivo (Nivolumab) vs Zynyz (retifanlimab-dlwr)
Opdivo (nivolumab) and Zynlonta (loncastuximab tesirine-lpyl, not Zynyz) are both immunotherapy drugs, but they target different mechanisms within the immune system to fight cancer. Opdivo is a PD-1 inhibitor used in various types of cancer, including melanoma, lung cancer, and kidney cancer, and works by blocking a pathway that restricts the immune system from attacking cancer cells. Zynlonta, on the other hand, is an antibody-drug conjugate that targets CD19, a protein expressed on the surface of certain B-cell lymphomas, and is used specifically for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. For someone deciding on which medicine is right for them, it is crucial to consider the specific type of cancer they have, as well as their overall health, previous treatments, and the specific indications and approval status of each drug. Consulting with a healthcare provider who can evaluate the individual's unique medical condition and history is essential for making an informed decision between these two treatments.
Difference between Opdivo and Zynyz
| Metric | Opdivo (Nivolumab) | Zynyz (retifanlimab-dlwr) |
|---|---|---|
| Generic name | Nivolumab | Retifanlimab-dlwr |
| Indications | Various types of cancers including melanoma, lung cancer, and more | Advanced squamous cell carcinoma of the anal canal (SCAC) for patients who have progressed on or after platinum-based chemotherapy |
| Mechanism of action | PD-1 inhibitor that enhances T-cell function against cancer cells | PD-1 inhibitor that enhances T-cell function against cancer cells |
| Brand names | Opdivo | Zynyz |
| Administrative route | IV infusion | IV infusion |
| Side effects | Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, etc. | Fatigue, rash, diarrhea, musculoskeletal pain, abdominal pain, constipation, decreased appetite, etc. |
| Contraindications | Severe hypersensitivity to nivolumab or any of its excipients | Severe hypersensitivity to retifanlimab or any of its excipients |
| Drug class | Immune checkpoint inhibitor | Immune checkpoint inhibitor |
| Manufacturer | Bristol Myers Squibb | Incysus Therapeutics, Inc. |
Efficacy
Opdivo (Nivolumab) Efficacy in Skin Cancer
Opdivo, known generically as Nivolumab, is a medication that has shown significant efficacy in the treatment of skin cancer, particularly malignant melanoma. As an immune checkpoint inhibitor, it works by blocking the PD-1 protein on the surface of T-cells, allowing the immune system to better detect and destroy cancer cells. In clinical trials, Nivolumab has demonstrated an ability to improve overall survival rates in patients with advanced melanoma. The CheckMate-067 trial, a pivotal study, showed that Nivolumab, alone or in combination with another immunotherapy drug, ipilimumab, significantly increased progression-free survival compared to ipilimumab alone.
Patients treated with Opdivo have also experienced durable responses, meaning that the effects of the treatment are long-lasting. This is particularly valuable in the context of advanced melanoma, where other treatments may not offer sustained benefits. The extension of survival times and improvement in the quality of life for patients with advanced skin cancers represents a significant advancement in the management of this disease.
Zynyz (Retifanlimab-dlwr) Efficacy in Skin Cancer
Zynyz, with the generic name retifanlimab-dlwr, is a lesser-known medication in the field of skin cancer treatment. It is an investigational anti-PD-1 antibody, similar in mechanism to Nivolumab, designed to help the immune system recognize and fight cancer cells. While there is ongoing research regarding its efficacy, the available data on retifanlimab-dlwr is not as extensive as that for Nivolumab. It is important to note that as of the knowledge cutoff in 2023, retifanlimab-dlwr may not have been approved for the treatment of skin cancer, and its efficacy and safety profile are still being evaluated in clinical trials.
For patients with skin cancer, the development of new treatments like Zynyz offers hope for more options and potentially improved outcomes. However, until more data is available from clinical trials, healthcare providers typically rely on established treatments with proven efficacy, such as Opdivo, especially for conditions like malignant melanoma where the disease can progress rapidly and requires prompt and effective treatment.
Regulatory Agency Approvals
Opdivo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Zynyz
-
Food and Drug Administration (FDA), USA
Access Opdivo or Zynyz today
If Opdivo or Zynyz are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us